Seeking Alpha

AcelRx Pharma (ACRX) surges 25% after saying that its under-the-tongue NanoTab system for...

AcelRx Pharma (ACRX) surges 25% after saying that its under-the-tongue NanoTab system for relieving pain after surgery came out on top in a direct head-to-head with morphine in a Phase III trial. Patients loved it and so did nurses. NanoTab system is being tested in two other late-stage studies. (PR)
Comments (1)
  • Microcap Growth Investor
    , contributor
    Comments (81) | Send Message
     
    ACRX is going much higher in 2013
    15 Nov 2012, 09:12 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|